Difference between revisions of "Forodesine (Fodosine)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
m |
||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
| − | ===[[T-cell lymphoma]]=== | + | ===[[Cutaneous T-cell lymphoma]]=== |
# Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Ann Oncol. 2014 Sep;25(9):1807-12. Epub 2014 Jun 19. [http://annonc.oxfordjournals.org/content/25/9/1807.full.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24948692 PubMed] | # Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Ann Oncol. 2014 Sep;25(9):1807-12. Epub 2014 Jun 19. [http://annonc.oxfordjournals.org/content/25/9/1807.full.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24948692 PubMed] | ||
| Line 13: | Line 13: | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:T-cell lymphoma medications]] | + | [[Category:Cutaneous T-cell lymphoma medications]] |
| − | [[Category: | + | [[Category:Drugs PMDA approved in 2017]] |
| + | [[Category:Orphan drug]] | ||
Revision as of 13:12, 21 July 2017
Mechanism of action
Purine nucleoside phosphorylase (PNP) inhibitor
Preliminary data
Cutaneous T-cell lymphoma
- Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Ann Oncol. 2014 Sep;25(9):1807-12. Epub 2014 Jun 19. link to original article PubMed
Also known as
Immucillin H